Video

Episode 5 - Elucidating the Economic Burden of MS

Multiple sclerosis (MS) manifests in various subtypes, with the bulk of disability occurring among individuals with progressive disease. According to Dr. Fred Lublin, the primary drivers of burden in MS are motor dysfunction and cerebellar dysfunction, and there are numerous facets that account for the growing burden of the neurological condition. Dr. Gary Owens noted that the economic burden of MS can really be categorized into 3 phases: Phase 1 is the cost burden associated with initial presentation and the ensuing, intense diagnostic evaluation period; Phase 2 is comprised of diagnosed patients receiving disease-modifying treatments; and Phase 3 consists of patients with progressive disease and the expenditures associated with chronic care.


Related Videos
Mike Fazio, Navista, Cardinal Health
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Kimlin Tam Ashing
Jaime Almandoz, MD, MBA
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo